Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cisplatin Generic Name & Formulations
Legal Class
Rx
General Description
Cisplatin 1mg/mL; soln for IV infusion after dilution; 50mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Platinum coordination complex.
How Supplied
Contact supplier
Manufacturer
Cisplatin Indications
Indications
Advanced bladder cancer.
Cisplatin Dosage and Administration
Adult
Administer pre- and post-treatment antiemetics as appropriate. Give by slow IV infusion. 50–70mg/m2 IV per cycle once every 3–4 weeks. Heavily pretreated patients: initially 50mg/m2 IV per cycle every 4 weeks. Subsequent cycles, other dosages, combination regimens, dose modifications: see full labeling.
Children
Not recommended.
Cisplatin Contraindications
Not Applicable
Cisplatin Boxed Warnings
Boxed Warning
Nephrotoxicity. Peripheral neuropathy. Nausea and vomiting. Myelosuppression.
Cisplatin Warnings/Precautions
Warnings/Precautions
Risk of dose-related nephrotoxicity or peripheral neuropathy, serious nausea, vomiting and myelosuppression. Baseline renal impairment or significant reductions in CrCl during therapy; reduce dose or consider alternatives. Monitor serum creatinine, BUN, CrCl, and electrolytes prior to initiation and as clinically indicated. Maintain adequate hydration before, during, and for 24hrs after dose. Consider magnesium supplementation as needed. Do baseline and periodic neurologic exam; consider discontinuation if Grade 3–4 neuropathy develops. Monitor blood counts before initiation, before each subsequent courses, and as clinically indicated. Monitor for infection. Have supportive equipment and medications readily available. Monitor audiometric and vestibular function (esp. children). Avoid extravasation. Elderly. Embryo-fetal toxicity. Use effective contraception during and for 14 months (females) or 11 months (males w. female partners) after last dose. Pregnancy; exclude status before initiation. Nursing mothers: not recommended.
Cisplatin Pharmacokinetics
See Literature
Cisplatin Interactions
Interactions
Potentiates nephrotoxicity with other nephrotoxic drugs. Increased ototoxicity with other ototoxic drugs. Avoid contact with aluminum (eg, needles, IV sets).
Cisplatin Adverse Reactions
Adverse Reactions
Nephrotoxicity, peripheral neuropathy, nausea, vomiting, myelosuppression, ototoxicity; hypersensitivity reactions (monitor), ocular toxicity, secondary malignancies, inj site reactions, impaired fertility.
Cisplatin Clinical Trials
See Literature
Cisplatin Note
Notes
Formerly known under the brand name Platinol.
Cisplatin Patient Counseling
See Literature
Cisplatin Generic Name & Formulations
Legal Class
Rx
General Description
Cisplatin 1mg/mL; soln for IV infusion after dilution; 50mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Platinum coordination complex.
How Supplied
Contact supplier
Manufacturer
Cisplatin Indications
Indications
Advanced ovarian cancer.
Cisplatin Dosage and Administration
Adult
Administer pre- and post-treatment antiemetics as appropriate. Give by slow IV infusion. 75–100mg/m2 IV per cycle once every 3–4 weeks on Day 1. Subsequent cycles, other dosages, combination regimens, dose modifications: see full labeling.
Children
Not recommended.
Cisplatin Contraindications
Not Applicable
Cisplatin Boxed Warnings
Boxed Warning
Nephrotoxicity. Peripheral neuropathy. Nausea and vomiting. Myelosuppression.
Cisplatin Warnings/Precautions
Warnings/Precautions
Risk of dose-related nephrotoxicity or peripheral neuropathy, serious nausea, vomiting and myelosuppression. Baseline renal impairment or significant reductions in CrCl during therapy; reduce dose or consider alternatives. Monitor serum creatinine, BUN, CrCl, and electrolytes prior to initiation and as clinically indicated. Maintain adequate hydration before, during, and for 24hrs after dose. Consider magnesium supplementation as needed. Do baseline and periodic neurologic exam; consider discontinuation if Grade 3–4 neuropathy develops. Monitor blood counts before initiation, before each subsequent courses, and as clinically indicated. Monitor for infection. Have supportive equipment and medications readily available. Monitor audiometric and vestibular function (esp. children). Avoid extravasation. Elderly. Embryo-fetal toxicity. Use effective contraception during and for 14 months (females) or 11 months (males w. female partners) after last dose. Pregnancy; exclude status before initiation. Nursing mothers: not recommended.
Cisplatin Pharmacokinetics
See Literature
Cisplatin Interactions
Interactions
Potentiates nephrotoxicity with other nephrotoxic drugs. Increased ototoxicity with other ototoxic drugs. Avoid contact with aluminum (eg, needles, IV sets).
Cisplatin Adverse Reactions
Adverse Reactions
Nephrotoxicity, peripheral neuropathy, nausea, vomiting, myelosuppression, ototoxicity; hypersensitivity reactions (monitor), ocular toxicity, secondary malignancies, inj site reactions, impaired fertility.
Cisplatin Clinical Trials
See Literature
Cisplatin Note
Notes
Formerly known under the brand name Platinol.
Cisplatin Patient Counseling
See Literature
Cisplatin Generic Name & Formulations
Legal Class
Rx
General Description
Cisplatin 1mg/mL; soln for IV infusion after dilution; 50mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Platinum coordination complex.
How Supplied
Contact supplier
Manufacturer
Cisplatin Indications
Indications
Advanced testicular cancer.
Cisplatin Dosage and Administration
Adult
Administer pre- and post-treatment antiemetics as appropriate. Give by slow IV infusion. 20mg/m2 IV daily for 5 days per cycle. Subsequent cycles, other dosages, combination regimens, dose modifications: see full labeling.
Children
Not recommended.
Cisplatin Contraindications
Not Applicable
Cisplatin Boxed Warnings
Boxed Warning
Nephrotoxicity. Peripheral neuropathy. Nausea and vomiting. Myelosuppression.
Cisplatin Warnings/Precautions
Warnings/Precautions
Risk of dose-related nephrotoxicity or peripheral neuropathy, serious nausea, vomiting and myelosuppression. Baseline renal impairment or significant reductions in CrCl during therapy; reduce dose or consider alternatives. Monitor serum creatinine, BUN, CrCl, and electrolytes prior to initiation and as clinically indicated. Maintain adequate hydration before, during, and for 24hrs after dose. Consider magnesium supplementation as needed. Do baseline and periodic neurologic exam; consider discontinuation if Grade 3–4 neuropathy develops. Monitor blood counts before initiation, before each subsequent courses, and as clinically indicated. Monitor for infection. Have supportive equipment and medications readily available. Monitor audiometric and vestibular function (esp. children). Avoid extravasation. Elderly. Embryo-fetal toxicity. Use effective contraception during and for 14 months (females) or 11 months (males w. female partners) after last dose. Pregnancy; exclude status before initiation. Nursing mothers: not recommended.
Cisplatin Pharmacokinetics
See Literature
Cisplatin Interactions
Interactions
Potentiates nephrotoxicity with other nephrotoxic drugs. Increased ototoxicity with other ototoxic drugs. Avoid contact with aluminum (eg, needles, IV sets).
Cisplatin Adverse Reactions
Adverse Reactions
Nephrotoxicity, peripheral neuropathy, nausea, vomiting, myelosuppression, ototoxicity; hypersensitivity reactions (monitor), ocular toxicity, secondary malignancies, inj site reactions, impaired fertility.
Cisplatin Clinical Trials
See Literature
Cisplatin Note
Notes
Formerly known under the brand name Platinol.
Cisplatin Patient Counseling
See Literature
